Provectus Biopharmaceuticals (PVCT) 10-K 29 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 25, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10025 Investment Drive
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37932
City Area Code	866
Local Phone Number	594-5999
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 26,775,067
Entity Common Stock, Shares Outstanding		419,447,119
Documents Incorporated by Reference [Text Block]	The information required by Part III is incorporated by reference to portions of the definitive proxy statement to be filed within 120 days after December 31, 2021, pursuant to Regulation 14A under the Securities Exchange Act of 1934 in connection with the 2022 annual meeting of stockholders.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	Los Angeles, CA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 682,984	$ 97,231
Restricted cash	2,423,958
Short-term receivables	5,107	3,930
Prepaid expenses and other current assets	329,908	322,518
Total Current Assets	3,441,957	423,679
Equipment and furnishings, less accumulated depreciation of $91,178 and $78,313, respectively	31,836	44,701
Operating lease right-of-use asset	39,563	120,821
Total Assets	3,513,356	589,201
Current Liabilities:
Accounts payable	1,287,459	956,860
Deposit for purchase of Series D-1 Preferred Stock	150,000
Unearned grant revenue	2,500,000
Other accrued expenses	2,002,486	1,500,782
Accrued interest	10,578	2,774,968
Accrued interest - related parties	6,044	1,766,493
Notes payable	238,452	236,228
Convertible notes payable	1,260,000	16,622,000
Convertible notes payable - related parties	200,000	6,770,000
Operating lease liability	45,617	84,383
Total Current Liabilities	7,700,636	30,711,714
Note payable, non-current portion		39,061
Operating lease liability, non-current portion		44,783
Total Liabilities	7,700,636	30,795,558
Stockholders’ Deficiency:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,447,119 and 398,807,037 shares issued and outstanding at December 31, 2021 and 2020, respectively	419,447	398,808
Additional paid-in capital	241,440,106	209,923,347
Accumulated other comprehensive loss	(34,467)	(34,097)
Accumulated deficit	(246,033,958)	(240,494,415)
Total Stockholders’ Deficiency	(4,187,280)	(30,206,357)
Total Liabilities and Stockholders’ Deficiency	3,513,356	589,201
Series B Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value	$ 9,219

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 91,178	$ 78,313
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Outstanding	419,447,119	398,807,037
Common shares, Issued	419,447,119	398,807,037
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	240,000	240,000
Preferred Stock, Shares Outstanding	0	100
Preferred stock, shares issued	0	100
Preferred Stock, Liquidation Preference Per Share	$ 0	$ 3,500
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	12,374,000	12,374,000
Preferred Stock, Shares Outstanding	12,373,247	0
Preferred stock, shares issued	12,373,247	0
Preferred Stock, Liquidation Preference Per Share	$ 14,164,889	$ 0
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	9,441,000	9,441,000
Preferred Stock, Shares Outstanding	9,218,449	0
Preferred stock, shares issued	9,218,449	0
Preferred Stock, Liquidation Preference Per Share	$ 105,532,804	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Expenses:
Research and development	$ 2,608,357	$ 2,812,760
General and administrative	2,063,897	2,150,816
Total Operating Expenses	4,672,254	4,963,576
Total Operating Loss	(4,672,254)	(4,963,576)
Other Income/(Expense):
EIDL grant		3,000
Research and development tax credit	31,315	27,694
Investment and interest income	4	3,415
Gain from forgiveness of PPP Loan and interest	63,094
Interest expense	(961,702)	(1,748,120)
Total Other Expense, Net	(867,289)	(1,714,011)
Net Loss	$ (5,539,543)	$ (6,677,587)
Basic and Diluted Loss Per Common Share	$ (0.01)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	408,223,004	393,252,321

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net Loss	$ (5,539,543)	$ (6,677,587)
Other Comprehensive Loss:
Foreign currency translation adjustments	(370)	(10,089)
Total Comprehensive Loss	$ (5,539,913)	$ (6,687,676)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficiency - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance	$ (30,206,357)	$ (24,072,112)
Common stock issued upon exercise of warrants	962,223	418,677
Options		64,294
Common stock	23,199	69,088
Warrants	488	1,372
Conversion of Series B Preferred Stock to Common Stock
Conversion of PRH Notes to Series D Preferred Stock	3,541,222
Conversion of PRH Notes to Series D-1 Preferred Stock	27,031,858
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss	(5,539,543)	(6,677,587)
Other comprehensive loss	(370)	(10,089)
Balance	(4,187,280)	(30,206,357)
Preferred Stock [Member] | Series B Preferred Stock [Member]
Balance
Balance, shares	100	100
Common stock issued upon exercise of warrants
Options
Common stock
Warrants
Conversion of Series B Preferred Stock to Common Stock
Conversion of Series B Preferred Stock to Common Stock, Shares	(100)
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss
Other comprehensive loss
Balance
Balance, shares		100
Preferred Stock [Member] | Series D Convertible Preferred Stock [Member]
Balance
Balance, shares
Common stock issued upon exercise of warrants
Options
Common stock
Warrants
Conversion of Series B Preferred Stock to Common Stock
Conversion of PRH Notes to Series D Preferred Stock	$ 12,373
Conversion of PRH Notes to Series D Preferred Stock, Shares	12,373,247
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss
Other comprehensive loss
Balance	$ 12,373
Balance, shares	12,373,247
Preferred Stock [Member] | Series D-1 Convertible Preferred Stock [Member]
Balance
Balance, shares
Common stock issued upon exercise of warrants
Options
Common stock
Warrants
Conversion of Series B Preferred Stock to Common Stock
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock	$ 9,441
Conversion of PRH Notes to Series D-1 Preferred Stock, shares	9,440,594
Conversion of Series D-1 Preferred Stock to Common Stock	$ (222)
Conversion of Series D-1 Preferred Stock to Common Stock, shares	(222,145)
Net loss
Other comprehensive loss
Balance	$ 9,219
Balance, shares	9,218,449
Common Stock [Member]
Balance	$ 398,808	$ 389,889
Balance, shares	398,807,037	389,889,475
Common stock issued upon exercise of warrants	$ 18,053	$ 7,856
Common stock issued upon exercise of warrants, shares	18,052,966	7,855,062
Options
Common stock	$ 300	$ 1,063
Common stock, shares	300,000	1,062,500
Warrants
Conversion of Series B Preferred Stock to Common Stock	$ 65
Conversion of Series B Preferred Stock to Common Stock, Shares	65,666
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series D-1 Preferred Stock to Common Stock	$ 2,221
Conversion of Series D-1 Preferred Stock to Common Stock, shares	2,221,450
Net loss
Other comprehensive loss
Balance	$ 419,447	$ 398,808
Balance, shares	419,447,119	398,807,037
Additional Paid-in Capital [Member]
Balance	$ 209,923,347	$ 209,378,835
Common stock issued upon exercise of warrants	944,170	410,821
Options		64,294
Common stock	22,899	68,025
Warrants	488	1,372
Conversion of Series B Preferred Stock to Common Stock	(65)
Conversion of PRH Notes to Series D Preferred Stock	3,528,849
Conversion of PRH Notes to Series D-1 Preferred Stock	27,022,417
Conversion of Series D-1 Preferred Stock to Common Stock	(1,999)
Net loss
Other comprehensive loss
Balance	241,440,106	209,923,347
AOCI Attributable to Parent [Member]
Balance	(34,097)	(24,008)
Common stock issued upon exercise of warrants
Options
Common stock
Warrants
Conversion of Series B Preferred Stock to Common Stock
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss
Other comprehensive loss	(370)	(10,089)
Balance	(34,467)	(34,097)
Retained Earnings [Member]
Balance	(240,494,415)	(233,816,828)
Common stock issued upon exercise of warrants
Options
Common stock
Warrants
Conversion of Series B Preferred Stock to Common Stock
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of Series D-1 Preferred Stock to Common Stock
Net loss	(5,539,543)	(6,677,587)
Other comprehensive loss
Balance	$ (246,033,958)	$ (240,494,415)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows From Operating Activities:
Net loss	$ (5,539,543)	$ (6,677,587)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	23,688	134,754
Non-cash lease expense	81,258	73,579
Depreciation	12,865	13,683
Amortization of patents		228,107
Gain on forgiveness of PPP Loan and interest	(63,094)
Changes in operating assets and liabilities
Short term receivables	(1,449)	50,321
Prepaid expenses	265,957	347,107
Accounts payable	331,148	(170,413)
Unearned grant revenue	2,500,000
Other accrued expenses	502,581	244,887
Operating lease liability	(83,549)	(77,916)
Accrued interest expense	956,834	1,747,683
Net Cash Used In Operating Activities	(1,013,304)	(4,085,795)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	2,960,000	3,125,000
Proceeds from issuance of convertible notes payable - related parties	200,000	100,000
Repayment of short-term note payable	(248,177)	(105,985)
Proceeds from note payable		62,500
Deposit for purchase of Series D-1 Preferred Stock	150,000
Proceeds from exercise of warrants	962,223	418,676
Net Cash Provided By Financing Activities	4,024,046	3,600,191
Effect of exchange rates on cash, cash equivalents, and restricted cash	(1,031)	(7,871)
Net Increase (Decrease) In Cash, Cash Equivalents, and Restricted Cash	3,009,711	(493,475)
Cash, Cash Equivalents, and Restricted Cash, Beginning of Period	97,231	590,706
Cash, Cash Equivalents, and Restricted Cash, End of Period	3,106,942	97,231
Cash and cash equivalents	682,984	97,231
Restricted cash	2,423,958
Cash and cash Equivalents, restricted cash	3,106,942	97,231
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Purchase of insurance policies financed by short-term note payable	273,347	318,775
Conversion of non-amended 2017 Notes to Series D Preferred Stock	3,541,222
Conversion of amended 2017 Notes and 2020 Notes to Series D-1 Preferred Stock	27,031,858
Conversion of Series D-1 Preferred Stock to Common stock	$ 222

Business Organization and Natur

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	1. Business Organization and Nature of Operations Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, with the aim of maximizing the curative impact of these medicines and achieving immunity from treated disease. These investigational drugs are based on a wholly owned class of small molecules called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”). ● Oncology: ® Oral formulations of cGMP RBS are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, such as head and neck, breast, colorectal, and testicular cancers. In vivo ● Pediatric Oncology: ● Hematology: In vivo ● Virology: In silico In vitro ● Microbiology: ● Ophthalmology: ● Dermatology: ® ● Animal Health: To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at December 31, 2021. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is still uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash, cash equivalents, and restricted cash were $ 3,106,942 at December 31, 2021 which includes the $ 2,423,958 of restricted cash resulting from a grant received from the State of Tennessee. The Company’s working capital deficiency was $ 4,258,679 and $ 30,288,035 as of December 31, 2021 and 2020, respectively. The improvement in working capital is primarily driven by the conversion of the 2017 and 2020 Notes into Series D and D-1 Preferred Stock. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10, PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, including the 2021 Financing (as defined in Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity and debt offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2022 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2021 and 2020, the Company’s cash equivalents consist of Treasury bills. Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 received in cash from the State of Tennessee less payments to vendors for expenses and deposits in the amount of $ 76,042 . See Note 14. Grants. Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of December 31, 2021 and 2020, the Company had cash, cash equivalent, and restricted cash balances in excess of FDIC insurance limits of $ 2,856,942 and $ 0 , respectively. Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2021 and 2020. Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are fully amortized as of December 31, 2021 and 2020. Patent amortization was $ 0 228,107 during the years ended December 31, 2021 and 2020, respectively. Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 8 – Short-term Receivables. Grant Income Grant income is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as unearned grant revenue and recognized as other income when qualifying costs are incurred. Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50 Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument. Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares December 31, 2021 2020 Warrants 512,500 87,264,164 Options 3,625,000 4,800,000 Convertible preferred stock 104,557,737 65,663 Total potentially dilutive shares 108,695,237 92,129,827 Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2021 and 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, restricted cash, receivables, other current assets, accounts payable, unearned grant income, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability. In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($ 22,053 and $ 407,851 at December 31, 2021 and $ 10,552 and $ 332,446 at December 31, 2020, respectively), and expense and other income accounts are translated at a weighted average exchange rate for the years then ended ($ 85,052 and $ 44,994 for the years ended December 31, 2021 and 2020, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive loss (“AOCL”), which is a separate component of stockholders’ deficiency. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denominated transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices. Recently Issued Accounting Pronouncements In August 2020, FASB issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” In October 2020, the FASB issued ASU 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. Recent Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” In March 2020, the FASB issued ASU No. 2020-03, “Codification Improvements to Financial Instruments”

Other Accrued Expenses

Other Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Other Accrued Expenses
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at December 31, 2021 and 2020: Schedule of Other Accrued Expenses 2021 2020 For The Years Ended December 31, 2021 2020 Accrued payroll and taxes $ 174,533 $ 31,504 Accrued vacation 42,871 25,452 Accrued directors’ fees 1,560,589 1,175,589 Accrued PPP interest - 438 Accrued other expenses 224,493 267,799 Total Other Accrued Expenses 2,002,486 1,500,782

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable The following summarizes convertible note activity during the years ended December 31, 2021 and 2020: Schedule of Convertible Notes Payable 2017 Notes 2020 Notes 2021 Notes Total Balance at January 1, 2020 $ 20,067,000 $ 100,000 $ - $ 20,167,000 Issuances - 3,225,000 - 3,225,000 Balance at December 31, 2020 20,067,000 3,325,000 - 23,392,000 Issuances - 1,700,000 1,460,000 3,160,000 Conversions (20,067,000 ) (5,025,000 ) - (25,092,000 ) Balance at December 31, 2021 $ - $ - $ 1,460,000 $ 1,460,000 2021 Financing On August 13, 2021, the Board approved a Financing Term Sheet (the “2021 Term Sheet”), which set forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $ 5,000,000 Pursuant to the 2021 Term Sheet, the 2021 Notes will either be paid back, convert into shares of the Company’s Series D-1 Preferred Stock, or convert into Company equity securities and/or debt instruments of certain future financings on or before twelve months after the issue date of a 2021 Note, subject to certain exceptions. The 2021 Financing is in the form of unsecured convertible loans from the investors and evidenced by convertible promissory notes (individually, a “2021 Note” and collectively, the “2021 Notes”). In addition to customary provisions, the 2021 Notes will contain the following provisions: (i) The 2021 Notes will bear interest at the rate of eight percent ( 8 (ii) In the event there is a change of control of the Board, the term of the 2021 Notes will be accelerated and all amounts due under the 2021 Notes may be immediately due and payable at the investors’ option; (iii) The outstanding principal amount and interest payment under the 2021 Notes may be paid back at maturity at the investors’ option; (iv) The outstanding principal amount and interest payable under the 2021 Notes may be convertible at the investors’ option into shares of Series D-1 Preferred Stock at a price per share equal to $ 2.8620 10 (v) In the event the Company conducts a qualified equity or debt financing and the Company receives gross proceeds in the aggregate amount of $ 20 The embedded conversion options associated with the 2021 Notes do not require bifurcation and treatment as a derivative liability and they do not represent a beneficial conversion feature because the effective conversion price is not at a discount to the commitment date market price. As of December 31, 2021, the Company had received 2021 Notes (defined above) proceeds of $ 1,460,000 , of which $ 200,000 is from a related party investor (an officer of the Company). 2020 Financing On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms of a financing in the form of secured convertible loans from investors that were evidenced by convertible promissory notes (the “2020 Notes”), which bear interest at the rate of eight percent ( 8 The outstanding principal amount and interest payable under the 2020 was convertible into shares of a new series of preferred stock at a price per share equal to $ 2.8620 , either (a) at any time after the new series of preferred stock is designated, at the sole discretion of the investors; or (b) automatically on June 20, 2021, subject to certain exceptions. See 2021 Conversions of Notes into Preferred Stock below. Over time, the Company received 2020 Notes proceeds of $ 5,025,000 100,000 2017 Financing On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company’s stockholders (the “PRH Group”), which was amended and restated effective as of March 19, 2017 (the “2017 Term Sheet”) that set forth the terms of a financing in the form of secured convertible loans from the PRH Group or other investors that were evidenced by convertible promissory notes (the “2017 Notes”), which bore interest at the rate of eight percent ( 8 %) per annum. The outstanding principal amount and interest payable under the 2017 Notes were convertible into shares of a new series of preferred stock at a price per share equal to $ 0.2862 , either (a) at any time after the new series of preferred stock is designated, at the sole discretion of the investors; or (b) automatically at the eighteen-month anniversary of the funding of the final tranche of 2017 Notes, subject to certain exceptions. See 2021 Conversions of Notes into Preferred Stock below. Over time, the Company received 2017 Notes proceeds of $ 20,067,000 6,670,000 3,050,000 3,620,000 Firm Commitment Previously, the Company had not designated the new series of preferred stock into which the 2017 Notes and the 2020 Notes (collectively the “Notes”) were convertible into. As a result, the Company did not analyze the Notes for a potential beneficial conversion feature, as the definition of a firm commitment had not been met since the Notes were not yet convertible. On June 17, 2021, the required Certificates of Designation were filed with the Delaware Secretary of State. Accordingly, a firm commitment was achieved. The Company analyzed the Notes for a beneficial conversion feature and determined that there was none because the Notes have an effective conversion price of $ 0.2862 0.07 2021 Conversions of Notes into Preferred Stock The following summarizes the conversion activity during the year ended December 31, 2021: Schedule of Conversion of Notes into Preferred Stock 2021 Conversions Into Preferred Stock Series D Series D-1 Total Principal converted $ 2,712,000 $ 22,380,000 $ 25,092,000 Accrued interest converted 829,222 4,651,858 5,481,080 Total converted $ 3,541,222 $ 27,031,858 $ 30,573,080 Conversion price $ 0.2862 $ 2.8620 Shares 12,373,247 9,440,594 21,813,841 Any fractional shares issuable pursuant to the formula were rounded up to the next whole share of Series D and Series D-1 Preferred Shares. The 2017 Notes originally provided that they were convertible into a new series of preferred stock at a price per share equal to $ 0.2862 In order to ensure that the Company had sufficient authorized shares of preferred stock into which the 2017 Notes would convert, yet keep the economic terms of the 2017 Notes substantially equivalent, on February 26, 2019, the Company entered into amendments (the “Amendments”) to the 2017 Notes (as amended, the “Amended 2017 Notes”) with a large majority of the holders of 2017 Notes to increase the conversion price by 10 times from $ 0.2862 to $ 2.8620 (the “New Conversion Price”) and to change the conversion ratio by providing that one share of Preferred Stock would be convertible into 10 shares of common stock (the “New Conversion Ratio”). The impact of the Amendments was to reduce by 10 times the number of shares of preferred stock into which the 2017 Notes would convert, while keeping the economic terms the same. The 2020 Notes had substantially similar terms to the Amended 2017 Notes, including being convertible into preferred stock at the New Conversion Price, with the Preferred Stock being convertible into Common Stock at the New Conversion Ratio. In order to (i) address the fact that a small minority of the holders of 2017 Notes did not execute the Amendments and (ii) ensure economic fairness for all of the holders of the 2017 Notes and 2020 Notes, on June 17, 2021, the Company designated two separate series of preferred stock into which the 2017 Notes and 2020 Notes would convert: (i) the Company’s Series D Convertible Preferred Stock, par value $ 0.001 per share was designated for the holders of 2017 Notes who did not execute the Amendments and (ii) the Company’s Series D-1 Convertible Preferred Stock, par value $ 0.001 per share was designated for the holders of Amended 2017 Notes and the holders of the 2020 Notes. On June 20, 2021, principal and interest in the aggregate amount of $ 3,541,222 , representing all of the outstanding non-amended 2017 Notes, was converted into 12,373,247 shares of Series D Convertible Preferred Stock at the Original Conversion Price of $ 0.2862 . Further on June 20, 2021, principal and interest in the aggregate amount of $ 27,031,858 , representing all of the outstanding Amended 2017 Notes and outstanding 2020 Notes was converted into 9,440,594 shares of Series D-1 Convertible Preferred Stock at the New Conversion Price of $ 2.862 . Any fractional shares issuable pursuant to the formula were rounded up to the next whole share of Series D and Series D-1 Preferred Shares. See Note 9. Stockholders’ Deficiency for additional information on the Series D and Series D-1 Convertible Preferred Stock. As a result of the conversion of the 2017 Notes and 2020 Notes into convertible preferred stock, all the security interests of these Notes in the Company’s intellectual property were released.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Notes Payable
Notes Payable	6. Notes Payable On April 20, 2020, the Company received a $ 62,500 The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses. 62,500 594 The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of December 31, 2021 and December 31, 2020, the balance of the note payable was $ 238,452 212,790

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During the years ended December 31, 2021 and 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 169,600 and $ 254,400 , respectively, for services rendered. Director fees for Mr. Horowitz for the year ending December 31, 2021 and 2020 were $ 75,000 and $ 75,000 , respectively. Accrued director fees for Mr. Horowitz as of December 31, 2021 and 2020 were $ 281,250 and $ 206,250 , respectively. Total amount owed to Capital Strategist as of December 31, 2021 and 2020 were $ 127,200 and $ 42,400 , respectively. Mr. Horowitz serves as both COO and a Director. See Note 5 and Note 8 for details of other related party transactions. Director fees during the years ended December 31, 2021 and 2020 were $ 385,000 383,065 1,560,589 1,175,589

Short-term Receivables

Short-term Receivables	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Short-term Receivables	8. Short-term Receivables Receivables at December 31, 2021 and 2020, include the Australian VAT tax credit and approximately $ 2,100,000 that is owed from Peter Culpepper. The Company has established a reserve of approximately $ 2,100,000 as of December 31, 2021 and 2020, which represents the amount Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement).

Stockholders_ Deficiency

Stockholders’ Deficiency	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Deficiency	9. Stockholders’ Deficiency Authorized Capital As of December 31, 2021, the Company was authorized to issue 1,000,000,000 0.001 25,000,000 0.001 one vote per share 240,000 12,374,000 9,441,000 2,945,000 Series B Preferred Stock On August 25, 2016, the Company filed the Series B Certificate of Designation with the Delaware Secretary of State. The Series B Certificate of Designation provides for the issuance of the Series B Preferred Stock with a par value $ 0.001 25.00 8 0.0533 During the year ended December 31, 2021, 100 shares of outstanding Series B Preferred Stock automatically converted, at the fifth-year anniversary of their issuance, into 65,666 shares of common stock, which represents $ 3,500 ($ 2,500 of stated value plus $ 1,000 of cumulative dividends) divided by the adjusted conversion price. Series D and Series D-1 Preferred Stock The rights, preferences and privileges of the Series D Preferred Stock and Series D-1 Preferred Stock (collectively, the “D-Series Preferred Stock”) are set forth in their respective Certificates of Designation. The Board of Directors of the Company approved each of the Certificates of Designation on June 14, 2021, and each Certificate of Designation was filed with the Delaware Secretary of State on June 17, 2021. The Series D Certificate of Designation established and designated 12,374,000 shares of Series D Preferred Stock. The Series D-1 Certificate of Designation established and designated 9,441,000 shares of Series D-1 Preferred Stock. On June 20, 2021, the Company issued 12,373,247 shares of Series D Preferred Stock upon the conversion of all of the outstanding 2017 Notes at the Original Conversion Price of $ 0.2862 and issued 9,440,594 shares of Series D-1 Preferred Stock upon the conversion of all outstanding Amended 2017 Notes and 2020 Notes at the New Conversion Price of $ 2.862 . See Note 5. Convertible Notes Payable for additional information on the conversion. During the year ended December 31, 2021, the Company received consideration of $ 150,000 from an investor in exchange for an aggregate of 52,411 shares of restricted Series D-1 Preferred Stock that have not yet been issued. During the year ended December 31, 2021, a holder of 222,145 2,221,450 Rank The Series D Preferred Stock and the Series D-1 Preferred Stock rank pari passu pari passu Dividends The D-Series Preferred Stock does not have any dividend preference but are entitled to receive, on a pari passu Liquidation Preference Upon the occurrence of the liquidation, winding-up or dissolution of the Company or certain mergers, corporate reorganizations or sales of the Company’s assets (each, a “Company Event”), holders of D-Series Preferred Stock will be entitled to receive a liquidation preference before any distributions are made to holders of any other class or series of the Company’s capital stock junior to the D-Series Preferred Stock. If a Company Event occurs within two years of June 20, 2021 (the “Date of Issuance”), the holders of D-Series D Preferred Stock will receive, for each share of D-Series Preferred Stock, an amount in cash equal to the Original Issue Price (as defined in the respective Certificates of Designation) multiplied by four. If a Company Event occurs from and after the second anniversary of the Date of Issuance, the holders of D-Series Preferred Stock will receive, for each share of D-Series Preferred Stock, an amount in cash equal to the Original Issue Price multiplied by six. The Original Issue Price for the Series D Preferred Stock is $ 0.2862 2.862 Voting Rights Holders of shares of D-Series Preferred Stock will vote together with the holders of common stock as a single class. Each share of Series D Preferred Stock carries the right to one vote per share. Each share of Series D-1 Preferred Stock carries the right to ten votes per share. The Company is not permitted to amend, alter or repeal its Certificate of Incorporation or Bylaws in a manner adverse to the relative rights, preferences, qualifications, limitations or restrictions of the D-Series Preferred Stock without the affirmative vote of a majority of the votes entitled to be cast by holders of outstanding shares of D-Series Preferred Stock, voting together as a single class with each share of D-Series Convertible Preferred Stock having a number of votes equal to the number of shares of common stock then issuable upon conversion of such share of D-Series Preferred Stock. Conversion The Series D Preferred Stock is convertible at the option of the holders thereof into shares of common stock based on a one-for-one conversion ratio. The Series D-1 Preferred Stock is convertible at the option of the holders thereof into shares of common stock based on a one-for-ten conversion ratio. The conversion ratio of the D-Series Preferred Stock is subject to adjustment for stock splits and combinations, recapitalizations, reclassifications, reorganizations, mergers, and consolidations. The D-Series Preferred Stock will automatically convert into shares of common stock upon the fifth anniversary of the date of issuance. Common Stock Issuances During the year ended December 31, 2020, the Company issued 1,062,500 shares of immediately vested restricted common stock with an aggregate issuance date value of $ 69,088 , which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. The following summarizes the Common Stock Issuances activity during the year ended December 31, 2020: Schedule of Common Stock Issuance Activity Type Date Stock Issuance Grant Date Value Contractor 4/1/2020 25,000 $ 1,150 Advisory Board Member 7/31/2020 25,000 1,800 Advisory Board Member 8/31/2020 12,500 1,013 Advisory Board Member 10/26/2020 25,000 1,750 Contractor 11/10/2020 25,000 1,625 Employee 11/10/2020 50,000 3,250 Board of Director 11/10/2020 100,000 6,500 Board of Director/Officer 11/10/2020 800,000 52,000 Total 1,062,500 $ 69,088 During the year ended December 31, 2021, the Company issued an aggregate of 300,000 shares of immediately vested restricted common stock with a grant date fair value of $ 23,199 for services. During the year ended December 31, 2021, the Company issued 2,221,450

Stock Incentive Plan and Warran

Stock Incentive Plan and Warrants	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Incentive Plan and Warrants	10. Stock Incentive Plan and Warrants The 2017 Amendment and Restatement of the Provectus Biopharmaceuticals, Inc. 2014 Equity Compensation Plan (the “2017 Equity Compensation Plan”) provides for the issuance of up to 20,000,000 10 16,437,500 There were no stock options granted during the year ended December 31, 2021. During the year ended December 31, 2020, the Company issued 2,425,000 five -year immediately vested stock options to an officer/director to purchase an aggregate of 2,425,000 shares of common stock with an exercise price of $ 0.12 per share. The stock options had an aggregate grant date fair value of $ 62,880 , which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. During the year ended December 31, 2020, the Company issued 100,000 five -year immediately vested stock options to a director to purchase an aggregate of 100,000 shares of common stock with an exercise price of $ 0.2862 per share. The stock options had an aggregate grant date fair value of $ 1,414 , which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. Stock options granted during the year ended December 31, 2020 were valued using the Black Scholes Model, with the following assumptions used: Schedule of Stock Options Granted Valued Using Black Scholes Model Expected terms (years) 2.50 Expected volatility 93 % Risk-free interest rate 0.23 % Expected dividend 0.00 % The following table summarizes option activity during the year ended December 31, 2021 and 2020: Summary of Option Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2020 3,000,000 $ 0.88 Granted 2,525,000 0.20 Forfeited (725,000 ) 0.88 Outstanding and exercisable at December 31, 2020 4,800,000 $ 0.46 Forfeited (1,175,000 ) 0.89 Outstanding and exercisable at December 31, 2021 3,625,000 $ 0.32 As of December 31, 2021, the intrinsic value of outstanding and exercisable options was $ 0 . The following table summarizes information about stock options outstanding at December 31, 2021: Summary of Stock Options Outstanding Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $ 0.12 2,425,000 3.90 2,425,000 $ 0.29 100,000 3.90 100,000 $ 0.67 200,000 1.60 200,000 $ 0.75 550,000 3.90 550,000 $ 0.84 150,000 0.50 150,000 $ 0.88 150,000 2.60 150,000 $ 0.93 50,000 0.40 50,000 3,625,000 3.55 3,625,000 Warrants During the year ended December 31, 2020, holders of warrants exercised warrants to purchase 7,855,062 0.053 418,677 7,855,062 During the year ended December 31, 2021, holders of warrants exercised warrants to purchase 18,052,966 0.053 962,223 18,052,966 68,723,698 During the year ended December 31, 2020, the Company issued 62,500 three-year immediately vested warrants to board members to purchase an aggregate of 62,500 shares of common stock with an exercise price of $ 0.2862 per share. The warrants had an aggregate grant date fair value of $ 1,372 , which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statements of operations. During the year ended December 31, 2021, the Company issued 25,000 three-year immediately vested warrants to an advisory board member to purchase an aggregate of 25,000 shares of common stock with exercise price of $ 0.28620 per share. The warrants had an aggregate grant date fair value of $ 488 , which was recognized immediately within stock compensation in general and administrative expenses. In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: Schedule of Assumptions of Warrants For the Years Ended December 31, 2021 2020 Contractual terms (years) 3.00 3.00 Expected volatility 92 % 93 95 % Risk-free interest rate 0.35 % .011 0.18 % Expected dividend 0.00 % 0.00 % The following table summarizes warrant activity during the year ended December 31, 2021 and 2020: Summary of Warrant Activity Number of Weighted Average Warrants Exercise Price Outstanding and exercisable at January 1, 2020 126,109,532 $ 0.29 Granted 62,500 0.29 Exercised (7,855,062 ) 0.05 Forfeited (31,052,806 ) 1.06 Outstanding and exercisable at December 31, 2020 87,264,164 $ 0.02 Granted 25,000 0.29 Exercised (18,052,966 ) 0.05 Forfeited (68,723,698 ) 0.05 Outstanding and exercisable at December 31, 2021 512,500 $ 0.92 As of December 31, 2021, the intrinsic value of outstanding and exercisable warrants was $ 0 The following table summarizes information about warrants outstanding at December 31, 2021: Summary of Warrants Outstanding Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Number of Warrant Weighted Average Remaining Life In Years Exercisable Number of Warrants $ 0.29 125,000 1.49 125,000 $ 1.00 18,000 2.39 18,000 $ 1.12 366,000 2.39 366,000 $ 2.00 3,500 2.39 3,500 512,500 2.17 512,500 Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2021 and 2020 are as follows: Schedule of Domestic and Foreign Loss Before Income Taxes 2021 2020 Years ended December 31 2021 2020 Domestic $ (5,454,489 ) $ (6,632,593 ) Foreign (85,053 ) (44,994 ) Net Pre-Tax Loss $ (5,539,542 ) $ (6,677,587 ) The income tax provision (benefit) consists of the following: Summary of Income Tax Provision (Benefit) Years ended December 31 2021 2020 Federal: Current $ - $ - Deferred 21.00 % 295,524 221,598 State and local: Current - - Deferred 5.14 % 72,262 54,186 26.14 % 367,786 275,784 Change in valuation allowance (367,786 ) (275,784 ) Income tax provision (benefit) $ - $ - The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate are as follows: Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate 2021 2020 Years Ended December 31 2021 2020 Tax benefit at federal statutory rate (21.0 )% (21.0 )% State income taxes, net of federal benefit (5.1 )% (5.1 )% Permanent differences (0.9 )% (0.7 )% Change in valuation allowance (7.2 )% (4.1 )% Prior year true-up 2.4 % 23.1 % Expiration of state net operating loss carryforwards 6.8 % 4.5 % Expiration of warrants and options 3.6 % 3.5 % Conversion of accrued interest to preferred stock 21.4 % 0.0 % Miscellaneous 0.0 % 0.0 % Effective income tax rate 0.0 % 0.0 % The components of the Company’s deferred income taxes are summarized below: Schedule of Components of Deferred Income Taxes 2021 2020 December 31 2021 2020 Deferred Tax Assets: Net operating loss carryforwards $ 43,453,746 $ 42,779,590 Stock-based compensation 186,772 428,726 Intangible assets 227,397 94,296 Research and development credit carryovers 3,049,608 2,985,215 Contribution carryovers 10,062 10,062 Accrued liabilities 505,038 1,503,190 Gross deferred tax assets 47,432,623 47,801,079 Deferred Tax Liabilities: Intangible assets - - Prepaid expenses (82,179 ) (82,839 ) Other (40,604 ) (40,603 ) Gross deferred tax liabilities (122,783 ) (123,442 ) Valuation allowance (47,309,840 ) (47,677,637 ) Deferred tax asset, net of valuation allowance $ - $ - Change in valuation allowance $ 367,786 $ 275,784 A valuation allowance against deferred tax assets is required if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets may not be realized. The Company is in the early stages of development and realization of the deferred tax assets is not considered more likely than not. As a result, the Company has recorded a full valuation allowance for the net deferred tax asset. Since inception of the Company on January 17, 2002, the Company has generated federal, state, and Australian tax net operating losses of approximately $ 170 million, $ 150 million, and $ 139 thousand, respectively. Under the Tax Cuts and Jobs Act, federal net operating losses incurred after December 31, 2017 may be carried forward indefinitely. The tax loss carryforwards of the Company may be subject to limitation by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation could reduce the Company’s ability to utilize net operating loss carryforwards. Federal net operating losses (“NOLS”) totaling $ 151.4 million expire in various amounts between 2022 and 2037. Federal NOLS totaling $ 18.6 million do not expire. Schedule of Net Operating Loss Year Year of Generated Expiration Amount 2002 2022 $ 5,794,541 2003 2023 1,520,649 2004 2024 3,571,227 2005 2025 5,530,815 2006 2026 7,192,407 2007 2027 10,218,952 2008 2028 7,017,372 2009 2029 9,573,948 2010 2030 10,344,298 2011 2031 11,225,047 2012 2032 11,193,882 2013 2033 10,273,181 2014 2034 9,075,738 2015 2035 17,455,417 2016 2036 19,710,699 2017 2037 11,703,175 2018 N/A 6,255,067 2019 N/A 4,085,063 2020 N/A 4,167,397 2021 N/A 4,166,084 Total NOLS $ 170,074,959 State NOLS totaling $ 150 Year Year of Generated Expiration Amount 2007 2022 $ 10,318,963 2008 2023 7,106,425 2009 2024 9,680,770 2010 2025 10,440,651 2011 2026 11,362,120 2012 2027 11,311,394 2013 2028 10,381,763 2014 2029 9,278,510 2015 2030 18,547,287 2016 2031 20,166,661 2017 2032 12,131,850 2018 2033 6,455,113 2019 2034 4,211,210 2020 2035 4,234,755 2021 2036 4,166,084 Total NOLS $ 149,793,556 Australia NOLS totaling $ 138,540 do not expire. Year Generated Year of Expiration Amount 2017 N/A $ 861 2018 N/A 54,101 2019 N/A 13,843 2020 N/A 13,384 2021 N/A 56,351 Total NOLS $ 138,540 The Company has determined that there are no uncertain tax positions as of December 31, 2021 or 2020. The Company files income tax returns in the U.S. federal jurisdiction and the state of Tennessee. The Company intends to permanently reinvest earnings in its foreign subsidiary. To date, the Company’s operations conducted by its Australian subsidiary consist primarily of research and development activities. As of December 31, 2021, there were no accumulated earnings and profits in the Company’s foreign subsidiary. At current tax rates, no additional Federal income taxes (net of available tax credits) would be payable if such earnings were to be repatriated.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases
Leases	12. Leases Leases The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022 . Payments are approximately $ 6,100 per month. On August 13, 2021, the Company negotiated a reduced rent from July 1, 2021 through December 31, 2021 in the amount of $ 6,100 Total expense for operating leases for the year ended December 31, 2021 was $ 86,545 , of which, $ 57,697 was included within research and development and $ 28,848 was included within general and administrative expenses on the consolidated statements of operations. Total expense for operating leases for the year ended December 31, 2020 was $ 90,821 , of which, $ 60,547 was included within research and development and $ 30,274 was included within general and administrative expenses on the consolidated statements of operations. As of December 31, 2021, the Company had no leases that were classified as a financing lease. As of December 31, 2021, the Company did not have additional operating and financing leases that have not yet commenced.  A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Years Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 82,678 $ 91,605 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 0.50 1.50 Weighted Average Discount Rate Operating leases 8.0 % 8.0 % Future minimum payments under non-cancellable lease as of December 31, 2021 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 46,687 Total future minimum lease payments 46,687 Less: amount representing imputed interest (1,070 ) Total $ 45,617

401(K) Profit Sharing Plan

401(K) Profit Sharing Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
401(K) Profit Sharing Plan	13. 401(K) Profit Sharing Plan The Company maintains a retirement plan under Section 401(k) of the Internal Revenue Code, which covers all eligible employees. All employees with U.S. source income are eligible to participate in the plan immediately upon employment. There was no

Grants

Grants	12 Months Ended
	Dec. 31, 2021
Grants
Grants	14. Grants On October 25, 2021, the Company received a grant award of $ 2,500,000 from the State of Tennessee for the study of animal cancers and dermatological disorders for the period October 15, 2021 to June 30, 2022. As of December 31, 2021, the grant award is recorded as unearned grant revenue liability on the accompanying consolidated balance sheets.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	15. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events The Company has evaluated events that have occurred after the balance sheet date and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. On February 23, 2022, the Company negotiated a continued reduced rent from January 1, 2022 through June 30, 2022 in the amount of $ 6,100

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2021 and 2020, the Company’s cash equivalents consist of Treasury bills.
Restricted Cash	Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 received in cash from the State of Tennessee less payments to vendors for expenses and deposits in the amount of $ 76,042 . See Note 14. Grants.
Cash Concentrations	Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of December 31, 2021 and 2020, the Company had cash, cash equivalent, and restricted cash balances in excess of FDIC insurance limits of $ 2,856,942 and $ 0 , respectively.
Equipment and Furnishings, net	Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.
Long-Lived Assets	Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2021 and 2020.
Patent Costs, net	Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are fully amortized as of December 31, 2021 and 2020. Patent amortization was $ 0 228,107 during the years ended December 31, 2021 and 2020, respectively. Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 8 – Short-term Receivables.
Grant Income	Grant Income Grant income is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as unearned grant revenue and recognized as other income when qualifying costs are incurred.
Research and Development	Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50
Convertible Instruments	Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument.
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares December 31, 2021 2020 Warrants 512,500 87,264,164 Options 3,625,000 4,800,000 Convertible preferred stock 104,557,737 65,663 Total potentially dilutive shares 108,695,237 92,129,827
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2021 and 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, restricted cash, receivables, other current assets, accounts payable, unearned grant income, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability. In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.
Foreign Currency Translation	Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($ 22,053 and $ 407,851 at December 31, 2021 and $ 10,552 and $ 332,446 at December 31, 2020, respectively), and expense and other income accounts are translated at a weighted average exchange rate for the years then ended ($ 85,052 and $ 44,994 for the years ended December 31, 2021 and 2020, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive loss (“AOCL”), which is a separate component of stockholders’ deficiency. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denominated transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2020, FASB issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” In October 2020, the FASB issued ASU 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.
Recent Adopted Accounting Pronouncements	Recent Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” In March 2020, the FASB issued ASU No. 2020-03, “Codification Improvements to Financial Instruments”

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares December 31, 2021 2020 Warrants 512,500 87,264,164 Options 3,625,000 4,800,000 Convertible preferred stock 104,557,737 65,663 Total potentially dilutive shares 108,695,237 92,129,827

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Other Accrued Expenses
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at December 31, 2021 and 2020: Schedule of Other Accrued Expenses 2021 2020 For The Years Ended December 31, 2021 2020 Accrued payroll and taxes $ 174,533 $ 31,504 Accrued vacation 42,871 25,452 Accrued directors’ fees 1,560,589 1,175,589 Accrued PPP interest - 438 Accrued other expenses 224,493 267,799 Total Other Accrued Expenses 2,002,486 1,500,782

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	The following summarizes convertible note activity during the years ended December 31, 2021 and 2020: Schedule of Convertible Notes Payable 2017 Notes 2020 Notes 2021 Notes Total Balance at January 1, 2020 $ 20,067,000 $ 100,000 $ - $ 20,167,000 Issuances - 3,225,000 - 3,225,000 Balance at December 31, 2020 20,067,000 3,325,000 - 23,392,000 Issuances - 1,700,000 1,460,000 3,160,000 Conversions (20,067,000 ) (5,025,000 ) - (25,092,000 ) Balance at December 31, 2021 $ - $ - $ 1,460,000 $ 1,460,000
Schedule of Conversion of Notes into Preferred Stock	The following summarizes the conversion activity during the year ended December 31, 2021: Schedule of Conversion of Notes into Preferred Stock 2021 Conversions Into Preferred Stock Series D Series D-1 Total Principal converted $ 2,712,000 $ 22,380,000 $ 25,092,000 Accrued interest converted 829,222 4,651,858 5,481,080 Total converted $ 3,541,222 $ 27,031,858 $ 30,573,080 Conversion price $ 0.2862 $ 2.8620 Shares 12,373,247 9,440,594 21,813,841

Stockholders_ Deficiency (Table

Stockholders’ Deficiency (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Common Stock Issuance Activity	The following summarizes the Common Stock Issuances activity during the year ended December 31, 2020: Schedule of Common Stock Issuance Activity Type Date Stock Issuance Grant Date Value Contractor 4/1/2020 25,000 $ 1,150 Advisory Board Member 7/31/2020 25,000 1,800 Advisory Board Member 8/31/2020 12,500 1,013 Advisory Board Member 10/26/2020 25,000 1,750 Contractor 11/10/2020 25,000 1,625 Employee 11/10/2020 50,000 3,250 Board of Director 11/10/2020 100,000 6,500 Board of Director/Officer 11/10/2020 800,000 52,000 Total 1,062,500 $ 69,088

Stock Incentive Plan and Warr_2

Stock Incentive Plan and Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock Options Granted Valued Using Black Scholes Model	Stock options granted during the year ended December 31, 2020 were valued using the Black Scholes Model, with the following assumptions used: Schedule of Stock Options Granted Valued Using Black Scholes Model Expected terms (years) 2.50 Expected volatility 93 % Risk-free interest rate 0.23 % Expected dividend 0.00 %
Summary of Option Activity	The following table summarizes option activity during the year ended December 31, 2021 and 2020: Summary of Option Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2020 3,000,000 $ 0.88 Granted 2,525,000 0.20 Forfeited (725,000 ) 0.88 Outstanding and exercisable at December 31, 2020 4,800,000 $ 0.46 Forfeited (1,175,000 ) 0.89 Outstanding and exercisable at December 31, 2021 3,625,000 $ 0.32
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2021: Summary of Stock Options Outstanding Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $ 0.12 2,425,000 3.90 2,425,000 $ 0.29 100,000 3.90 100,000 $ 0.67 200,000 1.60 200,000 $ 0.75 550,000 3.90 550,000 $ 0.84 150,000 0.50 150,000 $ 0.88 150,000 2.60 150,000 $ 0.93 50,000 0.40 50,000 3,625,000 3.55 3,625,000
Schedule of Assumptions of Warrants	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: Schedule of Assumptions of Warrants For the Years Ended December 31, 2021 2020 Contractual terms (years) 3.00 3.00 Expected volatility 92 % 93 95 % Risk-free interest rate 0.35 % .011 0.18 % Expected dividend 0.00 % 0.00 %
Summary of Warrant Activity	The following table summarizes warrant activity during the year ended December 31, 2021 and 2020: Summary of Warrant Activity Number of Weighted Average Warrants Exercise Price Outstanding and exercisable at January 1, 2020 126,109,532 $ 0.29 Granted 62,500 0.29 Exercised (7,855,062 ) 0.05 Forfeited (31,052,806 ) 1.06 Outstanding and exercisable at December 31, 2020 87,264,164 $ 0.02 Granted 25,000 0.29 Exercised (18,052,966 ) 0.05 Forfeited (68,723,698 ) 0.05 Outstanding and exercisable at December 31, 2021 512,500 $ 0.92
Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding at December 31, 2021: Summary of Warrants Outstanding Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Number of Warrant Weighted Average Remaining Life In Years Exercisable Number of Warrants $ 0.29 125,000 1.49 125,000 $ 1.00 18,000 2.39 18,000 $ 1.12 366,000 2.39 366,000 $ 2.00 3,500 2.39 3,500 512,500 2.17 512,500

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Domestic and Foreign Loss Before Income Taxes	The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2021 and 2020 are as follows: Schedule of Domestic and Foreign Loss Before Income Taxes 2021 2020 Years ended December 31 2021 2020 Domestic $ (5,454,489 ) $ (6,632,593 ) Foreign (85,053 ) (44,994 ) Net Pre-Tax Loss $ (5,539,542 ) $ (6,677,587 )
Summary of Income Tax Provision (Benefit)	The income tax provision (benefit) consists of the following: Summary of Income Tax Provision (Benefit) Years ended December 31 2021 2020 Federal: Current $ - $ - Deferred 21.00 % 295,524 221,598 State and local: Current - - Deferred 5.14 % 72,262 54,186 26.14 % 367,786 275,784 Change in valuation allowance (367,786 ) (275,784 ) Income tax provision (benefit) $ - $ -
Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate	The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate are as follows: Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate 2021 2020 Years Ended December 31 2021 2020 Tax benefit at federal statutory rate (21.0 )% (21.0 )% State income taxes, net of federal benefit (5.1 )% (5.1 )% Permanent differences (0.9 )% (0.7 )% Change in valuation allowance (7.2 )% (4.1 )% Prior year true-up 2.4 % 23.1 % Expiration of state net operating loss carryforwards 6.8 % 4.5 % Expiration of warrants and options 3.6 % 3.5 % Conversion of accrued interest to preferred stock 21.4 % 0.0 % Miscellaneous 0.0 % 0.0 % Effective income tax rate 0.0 % 0.0 %
Schedule of Components of Deferred Income Taxes	The components of the Company’s deferred income taxes are summarized below: Schedule of Components of Deferred Income Taxes 2021 2020 December 31 2021 2020 Deferred Tax Assets: Net operating loss carryforwards $ 43,453,746 $ 42,779,590 Stock-based compensation 186,772 428,726 Intangible assets 227,397 94,296 Research and development credit carryovers 3,049,608 2,985,215 Contribution carryovers 10,062 10,062 Accrued liabilities 505,038 1,503,190 Gross deferred tax assets 47,432,623 47,801,079 Deferred Tax Liabilities: Intangible assets - - Prepaid expenses (82,179 ) (82,839 ) Other (40,604 ) (40,603 ) Gross deferred tax liabilities (122,783 ) (123,442 ) Valuation allowance (47,309,840 ) (47,677,637 ) Deferred tax asset, net of valuation allowance $ - $ - Change in valuation allowance $ 367,786 $ 275,784
Schedule of Net Operating Loss	Schedule of Net Operating Loss Year Year of Generated Expiration Amount 2002 2022 $ 5,794,541 2003 2023 1,520,649 2004 2024 3,571,227 2005 2025 5,530,815 2006 2026 7,192,407 2007 2027 10,218,952 2008 2028 7,017,372 2009 2029 9,573,948 2010 2030 10,344,298 2011 2031 11,225,047 2012 2032 11,193,882 2013 2033 10,273,181 2014 2034 9,075,738 2015 2035 17,455,417 2016 2036 19,710,699 2017 2037 11,703,175 2018 N/A 6,255,067 2019 N/A 4,085,063 2020 N/A 4,167,397 2021 N/A 4,166,084 Total NOLS $ 170,074,959 State NOLS totaling $ 150 Year Year of Generated Expiration Amount 2007 2022 $ 10,318,963 2008 2023 7,106,425 2009 2024 9,680,770 2010 2025 10,440,651 2011 2026 11,362,120 2012 2027 11,311,394 2013 2028 10,381,763 2014 2029 9,278,510 2015 2030 18,547,287 2016 2031 20,166,661 2017 2032 12,131,850 2018 2033 6,455,113 2019 2034 4,211,210 2020 2035 4,234,755 2021 2036 4,166,084 Total NOLS $ 149,793,556 Australia NOLS totaling $ 138,540 do not expire. Year Generated Year of Expiration Amount 2017 N/A $ 861 2018 N/A 54,101 2019 N/A 13,843 2020 N/A 13,384 2021 N/A 56,351 Total NOLS $ 138,540

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Years Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 82,678 $ 91,605 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 0.50 1.50 Weighted Average Discount Rate Operating leases 8.0 % 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under non-cancellable lease as of December 31, 2021 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 46,687 Total future minimum lease payments 46,687 Less: amount representing imputed interest (1,070 ) Total $ 45,617

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents, and restricted cash	$ 3,106,942	$ 97,231	$ 590,706
Restricted cash	2,423,958
Working capital	$ 4,258,679	$ 30,288,035

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	108,695,237	92,129,827
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	512,500	87,264,164
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,625,000	4,800,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	104,557,737	65,663

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Oct. 25, 2021
Finite-Lived Intangible Assets [Line Items]
Unearned grant revenue	$ 2,500,000		$ 2,500,000
Payment to vendors for expense	76,042
Cash in excess FDIC insured amount	$ 2,856,942	0
Recognized income tax positions measured	50.00%
Foreign currency assets	$ 22,053	10,552
Foreign currency liabilities	407,851	332,446
Foreign currency translation expense and other income accounts	85,052	44,994
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Expected Amortization, Year One	$ 0	$ 228,107

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Other Accrued Expenses
Accrued payroll and taxes	$ 174,533	$ 31,504
Accrued vacation	42,871	25,452
Accrued directors’ fees	1,560,589	1,175,589
Accrued PPP interest		438
Accrued other expenses	224,493	267,799
Total Other Accrued Expenses	$ 2,002,486	$ 1,500,782

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Balance	$ 23,392,000	$ 20,167,000
Issuances	3,160,000	3,225,000
Conversions	(25,092,000)
Balance	1,460,000	23,392,000
2017 Note [Member]
Short-term Debt [Line Items]
Balance	20,067,000	20,067,000
Issuances
Conversions	(20,067,000)
Balance		20,067,000
2020 Note [Member]
Short-term Debt [Line Items]
Balance	3,325,000	100,000
Issuances	1,700,000	3,225,000
Conversions	(5,025,000)
Balance		3,325,000
2021 Note [Member]
Short-term Debt [Line Items]
Balance
Issuances	1,460,000
Conversions
Balance	$ 1,460,000

Schedule of Conversion of Notes

Schedule of Conversion of Notes into Preferred Stock (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Principal converted	$ 25,092,000
Accrued Interest Converted	5,481,080
Total converted	$ 30,573,080
Shares | shares	21,813,841
Series D Convertible Preferred Stock [Member]
Principal converted	$ 2,712,000
Accrued Interest Converted	829,222
Total converted	$ 3,541,222
Conversion price | $ / shares	$ 0.2862
Shares | shares	12,373,247
Series D-1 Convertible Preferred Stock [Member]
Principal converted	$ 22,380,000
Accrued Interest Converted	4,651,858
Total converted	$ 27,031,858
Conversion price | $ / shares	$ 2.8620
Shares | shares	9,440,594

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Jun. 20, 2021	Dec. 31, 2021	Dec. 31, 2020	Aug. 13, 2021	Dec. 31, 2019	Mar. 23, 2017
Short-term Debt [Line Items]
Proceeds from note payable		$ 2,960,000	$ 3,125,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Debt Conversion, Converted Instrument, Shares Issued		21,813,841
Firm Commitment [Member]
Short-term Debt [Line Items]
Share price		$ 0.07
Firm Commitment [Member] | Minimum [Member]
Short-term Debt [Line Items]
Effective conversion price		0.2862
Series D Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Effective conversion price		$ 0.2862
Debt Conversion, Converted Instrument, Shares Issued		12,373,247
Series D-1 Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Conversion of stock share issued		2,221,450
Effective conversion price		$ 2.8620
Debt Conversion, Converted Instrument, Shares Issued		9,440,594
Officers [Member]
Short-term Debt [Line Items]
Invested amount		$ 3,050,000
Board of Director [Member]
Short-term Debt [Line Items]
Invested amount		$ 3,620,000
2021 Note [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate, stated percentage		8.00%
Proceeds from note payable		$ 1,460,000
Related party investors		$ 200,000
2021 Note [Member] | Investors [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Preferred stock price per shares		$ 2.8620
Conversion of stock share issued		10
Proceeds from debt financing to convert		$ 20,000,000
2020 Note [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate, stated percentage					8.00%
Preferred stock price per shares		$ 2.8620
Proceeds from note payable		$ 5,025,000
Related party investors		100,000
2017 Note [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate, stated percentage						8.00%
Preferred stock price per shares						$ 0.2862
Proceeds from note payable		20,067,000
Related party investors		$ 6,670,000
2021 Financing [Member] | First and Final Tranche [Member] | 2021 Note [Member]
Short-term Debt [Line Items]
Financing arrangement amount				$ 5,000,000
2017 Financing [Member] | Series D and D1 Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Preferred stock conversion price		$ 0.2862
2017 Financing [Member] | Series D Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Preferred Stock, Par or Stated Value Per Share		0.001
2017 Financing [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Preferred Stock, Par or Stated Value Per Share		0.001
2017 Notes [Member] | Series D and D1 Convertible Preferred Stock [Member] | Minimum [Member]
Short-term Debt [Line Items]
Preferred stock conversion price		0.2862
2017 Notes [Member] | Series D and D1 Convertible Preferred Stock [Member] | Maximum [Member]
Short-term Debt [Line Items]
Preferred stock conversion price		$ 2.8620
Non Amended 2017 Financing [Mmber] | 2017 Notes [Member]
Short-term Debt [Line Items]
Aggregate outstanding principal and interest	$ 3,541,222
Non Amended 2017 Financing [Mmber] | 2017 Notes [Member] | Series D Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Effective conversion price	$ 0.2862
Debt Conversion, Converted Instrument, Shares Issued	12,373,247
Amended 2017 [Member] | 2017 Notes [Member]
Short-term Debt [Line Items]
Aggregate outstanding principal and interest	$ 27,031,858
Amended 2017 [Member] | 2017 Notes [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Effective conversion price	$ 2.862
Debt Conversion, Converted Instrument, Shares Issued	9,440,594

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Apr. 20, 2020	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Gain on forgiveness of PPP loan		$ 63,094
Note payable		238,452	$ 212,790
Paycheck Protection Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Proceeds from Loans	$ 62,500
Debt Instrument, Description	The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses.
Gain on forgiveness of PPP loan		62,500
Gain from forgiveness of PPP Loan interest		$ 594

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Accrued director fees	$ 1,560,589	$ 1,175,589
Directors fees	385,000	383,065
Mr Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Professional Fees	169,600	254,400
Accrued director fees	281,250	206,250
Director [Member] | Mr Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Professional Fees	75,000	75,000
Director [Member] | Mr Bruce Horowitz [Member] | Capital Strategist [Member]
Related Party Transaction [Line Items]
Professional Fees	$ 127,200	$ 42,400

Short-term Receivables (Details

Short-term Receivables (Details Narrative) - Peter Culpepper [Member] $ in Millions	Dec. 31, 2020USD ($)
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Accounts Receivable, before Allowance for Credit Loss	$ 2,100,000
Accounts Receivable, Allowance for Credit Loss	$ 2,100,000

Schedule of Common Stock Issuan

Schedule of Common Stock Issuance Activity (Details) - USD ($)	Nov. 10, 2020	Oct. 26, 2020	Aug. 31, 2020	Jul. 31, 2020	Apr. 01, 2020	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares							1,062,500
Share Based Compensation						$ 23,199	$ 69,088
Contractor One [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares					25,000
Share Based Compensation					$ 1,150
Advisory Board Member One [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares				25,000
Share Based Compensation				$ 1,800
Advisory Board Member Two [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares			12,500
Share Based Compensation			$ 1,013
Advisory Board Member Three [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares		25,000
Share Based Compensation		$ 1,750
Contractor Two [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares	25,000
Share Based Compensation	$ 1,625
Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares	50,000
Share Based Compensation	$ 3,250
Board of Director [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares	100,000
Share Based Compensation	$ 6,500
Boardof Director Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Based Compensation, Shares	800,000
Share Based Compensation	$ 52,000

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - USD ($)	Jun. 20, 2021	Aug. 25, 2016	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock, shares authorized			1,000,000,000	1,000,000,000
Common stock, par value			$ 0.001	$ 0.001
Preferred stock, shares authorized			25,000,000	25,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Common Stock, Voting Rights			one vote per share
Preferred stock, shares Undesignated			2,945,000
Stated value			$ 2,500
Cumulative Dividends			$ 1,000
Common Stock [Member]
Class of Stock [Line Items]
Conversion price		$ 0.0533
Preferred stock, shares converted			2,221,450
Common shares issued on conversion of stock			65,666
Conversion of Stock, Amount Converted			$ 3,500
Stock Issued During Period, Shares, New Issues			18,052,966	7,855,062
Stock Issued During Period, Shares, Restricted Stock Award, Gross			300,000	1,062,500
Stock Issued During Period, Value, Restricted Stock Award, Gross			$ 23,199	$ 69,088
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			240,000	240,000
Preferred Stock, Shares Issued			0	100
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			12,374,000	12,374,000
Preferred Stock, Shares Issued			12,373,247	0
Series D-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			9,441,000	9,441,000
Common shares issued on conversion of stock			2,221,450
Preferred Stock, Shares Issued			9,218,449	0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		0.001
Preferred stock, Stated value		$ 25
Preferred stock, dividend percentage		8.00%
Preferred stock, shares converted			100
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			12,374,000
Conversion price	$ 0.2862
Stock Issued During Period, Shares, New Issues	12,373,247
Shares Issued, Price Per Share			$ 0.2862
Preferred Stock, Voting Rights			Each share of Series D Preferred Stock carries the right to one vote per share.
Series D-1 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			9,441,000
Conversion price	$ 2.862
Preferred Stock, Shares Issued	9,440,594
Shares on conversion			222,145
Shares Issued, Price Per Share			$ 2.862
Preferred Stock, Voting Rights			Each share of Series D-1 Preferred Stock carries the right to ten votes per share.
Restricted Series D-1 Preferred Stock [Member] | Investor [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			52,411
Stock Issued During Period, Value, New Issues			$ 150,000

Schedule of Stock Options Grant

Schedule of Stock Options Granted Valued Using Black Scholes Model (Details)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Expected terms (years)	2 years 6 months
Expected volatility	93.00%
Risk free interest rate	0.23%
Expected dividends	0.00%

Summary of Option Activity (Det

Summary of Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding and exercisable, beginning balance	4,800,000	3,000,000
Weighted Average Exercise Price Outstanding and exercisable, beginning balance	$ 0.46	$ 0.88
Number of Options, Granted		2,525,000
Weighted Average Exercise Price, Granted		$ 0.20
Number of Options, Forfeited	(1,175,000)	(725,000)
Weighted Average Exercise Price, Forfeited	$ 0.89	$ 0.88
Number of Options Outstanding and exercisable, ending balance	3,625,000	4,800,000
Weighted Average Exercise Price Outstanding and exercisable, ending balance	$ 0.32	$ 0.46

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding	3,625,000
Weighted Average Remaining Contractual Life	3 years 6 months 18 days
Number Exercisable	3,625,000
Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.12
Number Outstanding	2,425,000
Weighted Average Remaining Contractual Life	3 years 10 months 24 days
Number Exercisable	2,425,000
Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.29
Number Outstanding	100,000
Weighted Average Remaining Contractual Life	3 years 10 months 24 days
Number Exercisable	100,000
Range Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.67
Number Outstanding	200,000
Weighted Average Remaining Contractual Life	1 year 7 months 6 days
Number Exercisable	200,000
Range Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.75
Number Outstanding	550,000
Weighted Average Remaining Contractual Life	3 years 10 months 24 days
Number Exercisable	550,000
Range Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.84
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	6 months
Number Exercisable	150,000
Range Six [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.88
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	2 years 7 months 6 days
Number Exercisable	150,000
Range Seven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.93
Number Outstanding	50,000
Weighted Average Remaining Contractual Life	4 months 24 days
Number Exercisable	50,000

Schedule of Assumptions of Warr

Schedule of Assumptions of Warrants (Details)	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants and Rights Outstanding, Term	3 years	3 years
Measurement Input, Price Volatility [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, measurement input	92
Measurement Input, Price Volatility [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, measurement input		93
Measurement Input, Price Volatility [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, measurement input		95
Measurement Input, Risk Free Interest Rate [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, measurement input	0.35
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, measurement input		0.011
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, measurement input		0.18
Measurement Input, Expected Dividend Rate [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, measurement input	0	0

Summary of Warrant Activity (De

Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Warrants Outstanding and exercisable, beginning balance	87,264,164	126,109,532
Weighted Average Exercise Price Outstanding and exercisable, beginning balance	$ 0.02	$ 0.29
Warrants, Granted	25,000	62,500
Weighted Average Exercise Price, Granted	$ 0.29	$ 0.29
Warrants, Exercised	(18,052,966)	(7,855,062)
Weighted Average Exercise Price, Exercised	$ 0.05	$ 0.05
Warrants, Forfeited	(68,723,698)	(31,052,806)
Weighted Average Exercise Price, Forfeited	$ 0.05	$ 1.06
Warrants Outstanding and exercisable, ending balance	512,500	87,264,164
Weighted Average Exercise Price Outstanding and exercisable, ending balance	$ 0.92	$ 0.02

Summary of Warrants Outstanding

Summary of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants Outstanding and exercisable, ending balance	512,500
Weighted Average Remaining Contractual Life, Warrants Exercisable	2 years 2 months 1 day
Number of Warrants, Exercisable	512,500
Warrant [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, Exercise price	$ 0.053	$ 0.053
Warrant [Member] | Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, Exercise price	$ 0.29
Warrants Outstanding and exercisable, ending balance	125,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	1 year 5 months 26 days
Number of Warrants, Exercisable	125,000
Warrant [Member] | Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, Exercise price	$ 1
Warrants Outstanding and exercisable, ending balance	18,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	2 years 4 months 20 days
Number of Warrants, Exercisable	18,000
Warrant [Member] | Range Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, Exercise price	$ 1.12
Warrants Outstanding and exercisable, ending balance	366,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	2 years 4 months 20 days
Number of Warrants, Exercisable	366,000
Warrant [Member] | Range Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants outstanding, Exercise price	$ 2
Warrants Outstanding and exercisable, ending balance	3,500
Weighted Average Remaining Contractual Life, Warrants Exercisable	2 years 4 months 20 days
Number of Warrants, Exercisable	3,500

Stock Incentive Plan and Warr_3

Stock Incentive Plan and Warrants (Details Narrative) - USD ($)	Aug. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 0
Warrants Exercised		25,000	62,500
Proceeds from warrant exercise		$ 962,223	$ 418,676
Number of warrants expired	68,723,698
Intrinsic value of outstanding and exercisable warrants		$ 0
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercised		18,052,966	7,855,062
Warrants exercise price		$ 0.053	$ 0.053
Proceeds from warrant exercise		$ 962,223	$ 418,677
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues		18,052,966	7,855,062
Officer or Director [Member] | Five-Year Immediately Vested [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issuable			2,425,000
Stock options expiration period			5 years
Stock options to purchase shares of common stock			2,425,000
Exercise price			$ 0.12
Aggregate grant date fair value			$ 62,880
Director [Member] | Five-Year Immediately Vested [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period			5 years
Stock options to purchase shares of common stock			100,000
Exercise price			$ 0.2862
Aggregate grant date fair value			$ 1,414
Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price		$ 0.28620	$ 0.2862
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		25,000	62,500
Fair Value Adjustment of Warrants		$ 488	$ 1,372
2017 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of available for issuance		16,437,500
2017 Equity Compensation Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issuable		20,000,000
Stock options period		10 years

Schedule of Domestic and Foreig

Schedule of Domestic and Foreign Loss Before Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Domestic	$ (5,454,489)	$ (6,632,593)
Foreign	(85,053)	(44,994)
Net Pre-Tax Loss	$ (5,539,542)	$ (6,677,587)

Summary of Income Tax Provision

Summary of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal: Current
Federal: Deferred tax rate	21.00%	21.00%
Federal: Deferred	$ 295,524	$ 221,598
State and local: Current
State and local: Deferred tax rate	5.14%	5.14%
State and local: Deferred	$ 72,262	$ 54,186
Effective deferred tax rate	26.14%	26.14%
Current income tax expense (benefit)	$ 367,786	$ 275,784
Change in valuation allowance	(367,786)	(275,784)
Income tax provision (benefit)

Schedule of Statutory Federal I

Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	(21.00%)	(21.00%)
State income taxes, net of federal benefit	(5.10%)	(5.10%)
Permanent differences	(0.90%)	(0.70%)
Change in valuation allowance	(7.20%)	(4.10%)
Prior year true-up	2.40%	23.10%
Expiration of state net operating loss carryforwards	6.80%	4.50%
Expiration of warrants and options	3.60%	3.50%
Conversion of accrued interest to preferred stock	21.40%	0.00%
Miscellaneous	0.00%	0.00%
Effective income tax rate	0.00%	0.00%

Schedule of Components of Defer

Schedule of Components of Deferred Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets:
Net operating loss carryforwards	$ 43,453,746	$ 42,779,590
Stock-based compensation	186,772	428,726
Intangible assets	227,397	94,296
Research and development credit carryovers	3,049,608	2,985,215
Contribution carryovers	10,062	10,062
Accrued liabilities	505,038	1,503,190
Gross deferred tax assets	47,432,623	47,801,079
Deferred Tax Liabilities:
Intangible assets
Prepaid expenses	(82,179)	(82,839)
Other	(40,604)	(40,603)
Gross deferred tax liabilities	(122,783)	(123,442)
Valuation allowance	(47,309,840)	(47,677,637)
Deferred tax asset, net of valuation allowance
Change in valuation allowance	$ 367,786	$ 275,784

Schedule of Net Operating Loss

Schedule of Net Operating Loss (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Operating Loss Carryforwards [Line Items]
Amount	$ 18,600,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Amount	$ 170,074,959
Federal [Member] | 2002 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2022
Amount	$ 5,794,541
Federal [Member] | 2003 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2023
Amount	$ 1,520,649
Federal [Member] | 2004 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2024
Amount	$ 3,571,227
Federal [Member] | 2005 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2025
Amount	$ 5,530,815
Federal [Member] | 2006 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2026
Amount	$ 7,192,407
Federal [Member] | 2007 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2027
Amount	$ 10,218,952
Federal [Member] | 2008 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2028
Amount	$ 7,017,372
Federal [Member] | 2009 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2029
Amount	$ 9,573,948
Federal [Member] | 2010 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2030
Amount	$ 10,344,298
Federal [Member] | 2011 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2031
Amount	$ 11,225,047
Federal [Member] | 2012 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2032
Amount	$ 11,193,882
Federal [Member] | 2013 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2033
Amount	$ 10,273,181
Federal [Member] | 2014 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2034
Amount	$ 9,075,738
Federal [Member] | 2015 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2035
Amount	$ 17,455,417
Federal [Member] | 2016 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2036
Amount	$ 19,710,699
Federal [Member] | 2017 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2037
Amount	$ 11,703,175
Federal [Member] | 2018 [Member]
Operating Loss Carryforwards [Line Items]
Amount	6,255,067
Federal [Member] | 2019 [Member]
Operating Loss Carryforwards [Line Items]
Amount	4,085,063
Federal [Member] | 2020 [Member]
Operating Loss Carryforwards [Line Items]
Amount	4,167,397
Federal [Member] | 2021 [Member]
Operating Loss Carryforwards [Line Items]
Amount	4,166,084
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Amount	$ 149,793,556
State and Local Jurisdiction [Member] | 2007 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2022
Amount	$ 10,318,963
State and Local Jurisdiction [Member] | 2008 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2023
Amount	$ 7,106,425
State and Local Jurisdiction [Member] | 2009 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2024
Amount	$ 9,680,770
State and Local Jurisdiction [Member] | 2010 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2025
Amount	$ 10,440,651
State and Local Jurisdiction [Member] | 2011 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2026
Amount	$ 11,362,120
State and Local Jurisdiction [Member] | 2012 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2027
Amount	$ 11,311,394
State and Local Jurisdiction [Member] | 2013 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2028
Amount	$ 10,381,763
State and Local Jurisdiction [Member] | 2014 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2029
Amount	$ 9,278,510
State and Local Jurisdiction [Member] | 2015 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2030
Amount	$ 18,547,287
State and Local Jurisdiction [Member] | 2016 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2031
Amount	$ 20,166,661
State and Local Jurisdiction [Member] | 2017 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2032
Amount	$ 12,131,850
State and Local Jurisdiction [Member] | 2018 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2033
Amount	$ 6,455,113
State and Local Jurisdiction [Member] | 2019 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2034
Amount	$ 4,211,210
State and Local Jurisdiction [Member] | 2020 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2035
Amount	$ 4,234,755
State and Local Jurisdiction [Member] | 2021 [Member]
Operating Loss Carryforwards [Line Items]
Year Expired	2036
Amount	$ 4,166,084
Australian [Member]
Operating Loss Carryforwards [Line Items]
Amount	138,540
Australian [Member] | 2017 [Member]
Operating Loss Carryforwards [Line Items]
Amount	861
Australian [Member] | 2018 [Member]
Operating Loss Carryforwards [Line Items]
Amount	54,101
Australian [Member] | 2019 [Member]
Operating Loss Carryforwards [Line Items]
Amount	13,843
Australian [Member] | 2020 [Member]
Operating Loss Carryforwards [Line Items]
Amount	13,384
Australian [Member] | 2021 [Member]
Operating Loss Carryforwards [Line Items]
Amount	$ 56,351

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Dec. 31, 2021USD ($)
Operating Loss Carryforwards [Line Items]
Tax net operating losses	$ 18,600,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Tax net operating losses	170,074,959
Federal [Member] | Between 2022 and 2037 [Member]
Operating Loss Carryforwards [Line Items]
Tax net operating losses	151,400,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Tax net operating losses	149,793,556
State and Local Jurisdiction [Member] | Between 2022 and 2036 [Member]
Operating Loss Carryforwards [Line Items]
Tax net operating losses	150,000,000
Australian [Member]
Operating Loss Carryforwards [Line Items]
Tax net operating losses	$ 138,540

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 82,678	$ 91,605
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Weighted Average Remaining Lease Term: Operating leases	6 months	1 year 6 months
Weighted Average Discount Rate: Operating leases	8.00%	8.00%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Dec. 31, 2021USD ($)
Leases
2022	$ 46,687
Total future minimum lease payments	46,687
Less: amount representing imputed interest	(1,070)
Total	$ 45,617

Leases (Details Narrative)

Leases (Details Narrative)	6 Months Ended	12 Months Ended
	Dec. 31, 2021USD ($)ft²	Dec. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)
Reduced payments for rent	$ 6,100
Research and Development Expense [Member]
Operating lease expense		$ 57,697	$ 60,547
General and Administrative Expense [Member]
Operating lease expense		28,848	30,274
Property Subject to Operating Lease [Member]
Operating lease expense		$ 86,545	$ 90,821
Knoxville, Tennessee [Member]
Area of Land | ft²	4,500	4,500
Lessee, Operating Lease, Term of Contract	5 years	5 years
Lease Expiration Date		Jun. 30, 2022
Payments for Rent		$ 6,100

401(K) Profit Sharing Plan (Det

401(K) Profit Sharing Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Contributions to 401(K) Profit Sharing Plan	$ 0	$ 0

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)	Dec. 31, 2021	Oct. 25, 2021	Dec. 31, 2020
Grants
Unearned grant revenue	$ 2,500,000	$ 2,500,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 23, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Reduced payments for rent		$ 6,100
Subsequent Event [Member]
Subsequent Event [Line Items]
Reduced payments for rent	$ 6,100